Bladder cancer cell viability inhibition and apoptosis induction by baicalein through targeting the expression of anti-apoptotic genes

被引:19
作者
Yang, Yong [1 ]
Liu, Kun [2 ]
Yang, Libo [1 ]
Zhang, Guoying [1 ]
机构
[1] Kunming Med Univ, Dept Urol, Affiliated Tumor Hosp, Kunming 650118, Yunnan, Peoples R China
[2] Kunming Med Univ, Affiliated Tumor Hosp, Dept Cadres Med, 519 Kunzhou Rd, Kunming 650118, Yunnan, Peoples R China
关键词
Survivin; Bladder cancer; Apoptosis; Viability; Reduction; PERINEURAL INVASION; CISPLATIN; PATHWAYS;
D O I
10.1016/j.sjbs.2017.03.014
中图分类号
Q [生物科学];
学科分类号
07 ; 0710 ; 09 ;
摘要
The study was aimed to investigate the effect of baicalein, a flavonoid molecule isolated from the plant Oroxylum indicum on bladder cancer cell viability. The results revealed that baicalein treatment of T24 and 253J bladder cancer cells targeted the expression of mRNA and proteins corresponding to the anti-apoptotic genes. RT-PCR assay showed that anti-apoptotic genes were markedly over-expressed in the bladder cancer cells. Exposure of the bladder cancer cells to baicalein at 5 mg/mL doses for 72 h led to reduction in the expression of mRNA levels of antiapoptotic genes. In T24 cells, the levels of BCL2, Bcl-xL, XIAP and surviving was reduced by 65, 69, 58 and 72%, respectively. In T24 and 253J cells exposure to baicalein for 72 h resulted respectively in 39 and 46% reduction in cell viability. Baicalein treatment also induced apoptosis in the bladder cancer cells. In T24 and 253J cells baicalein treatment at 5 mg/mL for 72 h induced apoptosis in 79 and 86% cells respectively. Thus, baicalein mediated reduction in antiapoptotic gene expression inhibits viability and induces apoptosis in bladder cancer cells. Therefore, baicalein is of therapeutic importance for the development of bladder cancer treatment strategy. (C) 2017 The Authors. Production and hosting by Elsevier B.V. on behalf of King Saud University. This is an open access article under the CC BY-NC-ND license (http://creativecommons.org/licenses/by-nc-nd/4.0/).
引用
收藏
页码:1478 / 1482
页数:5
相关论文
共 26 条
[1]  
Antonisamy P., 2015, South Indian J. Bio. Sci., V1, P34
[2]  
Balamurugan R., 2015, South Indian J. Biol. Sci, V1, P47
[3]   Control of mitochondrial apoptosis by the Bcl-2 family [J].
Brunelle, Joslyn K. ;
Letai, Anthony .
JOURNAL OF CELL SCIENCE, 2009, 122 (04) :437-441
[4]   Apoptosis in cancer: Key molecular signaling pathways and therapy targets [J].
Burz, Claudia ;
Berindan-Neagoe, Ioana ;
Balacescu, Ovidiu ;
Irimie, Alexandru .
ACTA ONCOLOGICA, 2009, 48 (06) :811-821
[5]   Cystectomy for bladder cancer: A contemporary series [J].
Dalbagni, G ;
Genega, E ;
Hashibe, M ;
Zhang, ZF ;
Russo, P ;
Herr, H ;
Reuter, V .
JOURNAL OF UROLOGY, 2001, 165 (04) :1111-1116
[6]   Efficacy and tolerability of concurrent weekly low dose cisplatin during radiation treatment of localised muscle invasive bladder transitional cell carcinoma: A report of two sequential Phase II studies from the Trans Tasman Radiation Oncology Group [J].
Gogna, Nirdosh Kumar ;
Matthews, John H. L. ;
Turner, Sandra L. ;
Mameghan, Heidi ;
Duchesne, Gillian M. ;
Spry, Nigel ;
Berry, Martin P. ;
Keller, Jacqui ;
Tripcony, Lee .
RADIOTHERAPY AND ONCOLOGY, 2006, 81 (01) :9-17
[7]  
Gopalakrishnan, 2015, S IND J BIOL SCI, V1, P60, DOI 10.22205/sijbs/2015/v1/i2/100420
[8]   RTOG 97-06: Initial report of a phase I-II trial of selective bladder conservation using TURBT, twice-daily accelerated irradiation sensitized with cisplatin, and adjuvant MCV combination chemotherapy [J].
Hagan, MP ;
Winter, KA ;
Kaufman, DS ;
Wajsman, Z ;
Zietman, AL ;
Heney, NM ;
Toonkel, LM ;
Jones, CU ;
Roberts, JD ;
Shipley, WU .
INTERNATIONAL JOURNAL OF RADIATION ONCOLOGY BIOLOGY PHYSICS, 2003, 57 (03) :665-672
[9]   Hallmarks of Cancer: The Next Generation [J].
Hanahan, Douglas ;
Weinberg, Robert A. .
CELL, 2011, 144 (05) :646-674
[10]   Do vascular, lymphatic, and perineural invasion have prognostic implications for bladder cancer after radical cystectomy? [J].
Hong, SK ;
Kwak, C ;
Jeon, HG ;
Lee, E ;
Lee, SE .
UROLOGY, 2005, 65 (04) :697-702